Mamlouk, K <br/><br/>
Modification of the Bu/Cy myeloablative regimen using daily parenteral busulfan: reduced toxicity without the need for pharmacokinetic monitoring.  [electronic resource] 

 -  Bone marrow transplantation  Apr 2005 
 - 747-54 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>0268-3369 
<br/><br/><label>Standard No.: </label>10.1038/sj.bmt.1704871  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Area Under Curve<br/>Busulfan--administration & dosage<br/>Cyclophosphamide--administration & dosage<br/>Female<br/>Graft vs Host Disease--prevention & control<br/>Hematopoietic Stem Cell Transplantation--methods<br/>Humans<br/>Immunosuppressive Agents--administration & dosage<br/>Male<br/>Middle Aged<br/>Prospective Studies<br/>Radiometry<br/>Retrospective Studies<br/>Time Factors<br/>Transplantation Conditioning<br/>Treatment Outcome